formally known as gpha

Same medicine. Same results.
Lower cost.

 
RX solutions
 
 
 
Generic medicines drive savings, not costs.
The generic pharmaceutical industry plays an important role in the health system and generic drug manufacturers are true drivers of health system value — generating savings and enhancing access for patients, public programs, taxpayers, employers and others who rely on more affordable medicines. The 2016 Generic Drug Savings and Access in the U.S. report shows that generic pharmaceuticals saved the U.S. health system $227 billion in 2015.
 
 
 

 

GPhA’s 5 Policy Prescriptions

Explore the five policy prescriptions below that policymakers can enact today to spur competition and bring more safe, effective and affordable generic drugs within reach for millions of Americans.

 

Approved a regulatory pathway to remove duplicative international drug approval processes Repeal the generic drug penalty in Medicaid Maintain IPR patent review and put an end to Evergreening Pass the CREATES Act in the Senate and FAST Generics Act in the House Increase generic utilization amoung LIS Medicare population
 
Generic Drug Report 2016

 

Recent Research

The 2016 Generic Drug Savings and Access in the U.S. report shows that generic pharmaceuticals saved the U.S. health system $227 billion in 2015.
 

 

Savings by State

Explore the analysis of generic drug savings in 2016 by state, therapy area and public program. Data compiled by the QuintilesIMS Institute.
 
Generic Drug Savings by State
 
 

 

Press Releases

 

Related Information